Skip to main content
Biosynex logo

Biosynex — Investor Relations & Filings

Ticker · ALBIO ISIN · FR0011005933 LEI · 969500H4BGE1HBLGP566 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2023-09-01 Declaration of Voting R…
Country FR France
Listing PA ALBIO

About Biosynex

https://www.biosynex.com/en/

Biosynex is a company that specializes in the design, manufacture, and distribution of medical diagnostic solutions. Its core product line consists of Rapid Diagnostic Tests (RDTs) for both professional use in clinical settings and for self-testing by the general public. The professional portfolio includes point-of-care (POC) instruments, molecular biology diagnostics (such as PCR tests), and a wide array of immunodiagnostic assays. For the consumer market, Biosynex offers various self-tests and a range of prevention and monitoring devices, including thermometers, blood pressure monitors, and pulse oximeters. The company focuses on providing simple, rapid, and effective tools for screening, diagnosis, and prevention.

Recent filings

Filing Released Lang Actions
BIOSYNEX SA: DECLARATION DU NOMBRE D’ACTIONS ET DES DROITS DE VOTE AU 31 AOÛT 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled "DECLARATION DU NOMBRE D'ACTIONS ET DES DROITS DE VOTE AU 31 AOÛT 2023" (Declaration of the number of shares and voting rights as of August 31, 2023). It explicitly references French regulatory articles (Article L.233-8 II du Code de commerce – Article 223-16 du Règlement général de l'Autorité des Marchés Financiers) and provides a table detailing the total number of shares and the total net voting rights as of a specific date. This content directly corresponds to the definition of a Declaration of Voting Results & Voting Rights Announcement, which is classified as AGM-R if related to an AGM, or DVA if it's a formal declaration of voting rights structure. Since it is a formal declaration of the total number of voting rights, it fits the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA). Although it mentions a date, it is not a comprehensive financial report (like 10-K or IR) nor a proxy solicitation (PSI).
2023-09-01 French
BIOSYNEX SA: DECLARATION DU NOMBRE D’ACTIONS ET DES DROITS DE VOTE AU 31 JUILLET 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "DECLARATION DU NOMBRE D'ACTIONS ET DES DROITS DE VOTE AU 31 JUILLET 2023" (Declaration of the number of shares and voting rights as of July 31, 2023). It explicitly references Article L.233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation, which mandate the publication of the total number of shares and voting rights. This content directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes or related statutory disclosures about voting power.
2023-08-01 French
BIOSYNEX SA: ACQUISITION DE LA TOTALITE DU CAPITAL DE LA SOCIETE QUALIGEN INC. PAR CHEMBIO INC.
M&A Activity Classification · 99% confidence The document text is a press release written in French announcing the acquisition of QUALIGEN Inc. by CHEMBIO INC. (a subsidiary of BIOSYNEX). It details the transaction, the acquired company's business (immunoanalysis platform), strategic rationale (strengthening US presence, synergies), and includes quotes from the CEO. This type of announcement, detailing a significant corporate transaction like a merger or acquisition, directly corresponds to the 'M&A Activity' definition. The relevant code is TAR (M&A Activity). It is not a formal regulatory filing like a 10-K, nor is it a short announcement of a report (RPA/RNS), as it contains substantial operational and strategic details about the transaction itself. The document length (4939 chars) is sufficient to be considered a substantive announcement, not just a placeholder.
2023-07-21 French
BIOSYNEX SA: CHIFFRE D’AFFAIRES DU 1er SEMESTRE 2023 : 42,8 M€
Earnings Release Classification · 95% confidence The document is a press release announcing the company's revenue (chiffre d'affaires) for the first half of 2023. It provides key financial highlights, a breakdown of revenue by division, and management commentary on business trends and acquisitions. It is not a full interim report (which would include comprehensive financial statements) but rather an initial announcement of financial results, which fits the definition of an Earnings Release (ER). H1 2023
2023-07-20 French
BIOSYNEX SA: DÉCLARATION DU NOMBRE D’ACTIONS ET DES DROITS DE VOTE AU 30 JUIN 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "DECLARATION DU NOMBRE D'ACTIONS ET DES DROITS DE VOTE AU 30 JUIN 2023" (Declaration of the number of shares and voting rights as of June 30, 2023). It explicitly references Article L.233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation, which mandate the publication of the total number of shares and voting rights. This specific disclosure relates to the capital structure and voting power, which is a regulatory requirement often tied to shareholder meetings or general corporate governance disclosures. Among the provided codes, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most appropriate fit for a formal declaration of the total number of voting rights outstanding on a specific date, even if it's not the *result* of a vote, but the underlying count used for voting.
2023-07-04 French
BIOSYNEX SA: PRISE DE CONTROLE ET ACQUISITION DE LA TOTALITE DU CAPITAL DE LA SOCIETE PROCISEDX
M&A Activity Classification · 99% confidence The document announces a significant corporate action: BIOSYNEX acquiring the remaining shares of ProciseDx, detailing the terms of the acquisition, strategic rationale (US presence, biotherapy monitoring), and mentioning future communication dates (Q2 2023 revenue). This is a major corporate event announcement, not a routine periodic financial report (like 10-K or IR) or a simple management change. It relates directly to corporate structure and financing/acquisition activity. Given the options, 'M&A Activity' (TAR) is the most appropriate fit for a takeover/acquisition announcement. It is too detailed to be a general 'Regulatory Filing' (RNS) and does not fit the specific definitions of other codes like ER, DIV, or DIRS.
2023-06-12 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.